≡

Multiplex Assay Kit for Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay)

CSPG2; VS; ERVR; PG-M; WGN1; Chondroitin Sulfate Proteoglycan 2; Chondroitin sulfate proteoglycan core protein 2; Glial hyaluronate-binding; Large fibroblast proteoglycan

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 95-102 98
EDTA plasma(n=5) 92-99 95
heparin plasma(n=5) 88-95 92
sodium citrate plasma(n=5) 90-97 94

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-88% 79-93% 78-91% 99-105%
EDTA plasma(n=5) 89-104% 79-102% 87-97% 85-96%
heparin plasma(n=5) 97-105% 85-93% 78-96% 80-94%
sodium citrate plasma(n=5) 98-105% 81-102% 98-105% 98-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:VCAN) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Plos one Tumor-Produced Versican V1 Enhances hCAP18/LL-37 Expression in Macrophages through Activation of TLR2 and Vitamin D3 Signaling to Promote Ovarian Cancer Progression In Vitro PubMed: PMC3570526
Clinica Chimica Acta Versican and its associated molecules: Potential diagnostic markers for multiple myeloma Pubmed:25623955
Journal of Cancer Research and Clinical Oncology Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma
RNA Biology Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signaling Pubmed: 31532704
miR-124-3p and miR-181a-5p Mediate AT1-Receptor Autoantibody Induced Fetal Rat Cardiac Remodeling via Increased VCAN Expression
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPB817Mu02 Recombinant Versican (VCAN) Positive Control; Immunogen; SDS-PAGE; WB.
RPB817Mu01 Recombinant Versican (VCAN) Positive Control; Immunogen; SDS-PAGE; WB.
PAB817Mu01 Polyclonal Antibody to Versican (VCAN) WB; IHC; ICC; IP.
PAB817Mu02 Polyclonal Antibody to Versican (VCAN) WB; IHC; ICC; IP.
SEB817Mu ELISA Kit for Versican (VCAN) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB817Mu Multiplex Assay Kit for Versican (VCAN) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.